Analysts' Actions: AMZN, BSX, DD, LOW, FSLR

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

AMC Networks ( AMCX) rated new Overweight at JP Morgan. $43 price target. Pullback has created an attractive buying opportunity in the growing company.

Amazon.com ( AMZN) rated new Outperform at Morgan Keegan. $210 price target. Company can continue to gain market share in North America.

Acme Packet ( APKT) rated new Neutral at JP Morgan. $29 price target. Inflection point in growth may still be several quarters away.

Bill Barrett ( BBG) downgraded to hold at TheStreet Ratings.

Biglari Holdings ( BH) downgraded to hold at TheStreet Ratings.

Broadcom ( BRCM) upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Valuation call, as earnings should rebound in 2012.

Boston Scientific ( BSX) downgraded at Goldman to Sell, Goldman Sachs said. Consensus estimates appear too high.

BorgWarner ( BWA) downgraded at UBS from Buy to Neutral, UBS said. $68 price target. Europe headwinds remain despite german OEM exposure.

Deckers ( DECK) downgraded at Sterne Agee from Buy to Underperform, Sterne Agee said. Estimates also cut, following disappointing channel checks for UGG. $72 price target.

First Solar ( FSLR) downgraded at Baird from Outperform to Neutral, Robert Baird said. $35 price target. Company slashed it guidance and the business is in a transition period.

Forest Oil ( FST) rated new Hold at Keybanc. Company still has to show that it can generate growth in newer shale areas.

Gulfport Energy ( GPOR) rated new Outperform at Credit Suisse. $41 price target. Utica shale should continue to drive growth.

Hospira ( HSP) rated new Sell at UBS. $25 price target. Recovery from manufacturing issues could be slow.

ITC ( ITC) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. Company can deliver above-average growth in the coming quarters. $79 price target.

Kior ( KIOR) upgraded at Baird from Underperform to Neutral, Robert Baird said. Valuation call, based on a $10 price target.

Laboratory Corp. ( LH) downgraded at Goldman to Sell, Goldman Sachs said. Industry is facing flat volumes and rising costs.

Lam Research ( LRCX) upgraded at Needham from Hold to Buy, Needham said. $46 price target. NVLS purchase will improve scale and customer leverage.

PerkinElmer ( PKI) upgraded at Goldman to Buy, Goldman Sachs said. Sentiment appears to have bottomed out for the group.

Skyworks ( SWKS) downgraded at Deutsche from Buy to Hold, Deutsche Bank said. $22 price target. Stock appears oversold, following a 37% decline.

Stryker ( SYK) downgraded at Goldman to Neutral, Goldman Sachs said. End-market demand remains weak.

Teco Energy ( TE) upgraded at Deutsche from Sell to Hold, Deutsche Bank said. $17 price target. Company remains should continue to deliver solid growth in the coming quarters.

Thermo Fisher ( TMO) rated new Outperform at Credit Suisse. $57 price target. Company can deliver consistent, double-digit earnings growth.

Thermo Fisher downgraded at Goldman to Neutral, Goldman Sachs said. Valuation call.

Waters ( WAT) rated new Neutral at Credit Suisse. Valuation call, based on an $80 price target.

Zions Bancorporation ( ZION) downgraded at KBW from Outperform to Market Perform, KBW said. Stock will likely remain range-bound, until more details emerge about its capital plan in March. $19 price target.

STOCK COMMENTS / EPS CHANGES

Agilent ( A) added to US Focus List at Credit Suisse. Company can deliver solid annual growth in the coming years and trades at a discount to the market.

Abbott Laboratories ( ABT) numbers lowered at Citigroup. Shares of ABT now seen reaching $46, according to Citigroup. Estimates also lowered as DMP sales targets look unrealistic. Sell rating.

Baxter ( BAX) cut from Conviction Buy List at Goldman. Company lacks near-term catalysts.

Broadcom ( BRCM) estimates raised at UBS through 2012, UBS said. Revises sales outlook to high end on better mobile and wireless demand.

ConAgra Foods ( CAG) estimates raised at Jefferies through 2012, Jefferies said. New $750 million share buyback authorization. Hold rating.

Crown Holdings ( CCK) numbers raised at Credit Suisse. Shares of CCK now seen reaching $44, according to Credit Suisse. Estimates also increased, as the company is buying back more stock. Outperform rating.

Carnival ( CCL) estimates lowered at Goldman through 2013, Goldman Sachs said. Company is facing higher fuel prices. Buy rating and $41 price target.

Delta Air Lines ( DAL) estimates lowered at UBS through 2012, UBS said. Higher non-fuel costs. Maintain $12 price target and Buy rating.

DuPont ( DD) target reduced at Credit to $50, according to Credit Suisse. Company faces near-term growth headwinds. Neutral rating.

Danaher ( DHR) estimates lowered at UBS through 2012 on macro challenges, UBS said. Maintain $58 price target and Buy rating.

E*Trade ( ETFC) estimates lowered at Goldman through 2012, Goldman Sachs said. Company is seeing lower trading activity.

FactSet Research Systems ( FDS) estimates lowered at Oppenheimer through 2012, Oppenheimer said. User growth seeing some pressure. Perform rating.

First Solar ( FSLR) numbers lowered at Jefferies. Shares of FSLR now seen reaching $38, Jefferies said. Estimates also lowered on terrible end market conditions. Hold rating.

First Solar numbers cut at Credit Suisse. Shares of FSLR now seen reaching $30, according to Credit Suisse. Estimates also reduced, given lower systems profitability. Neutral rating.

First Solar numbers lowered at UBS. Shares of FSLR now seen reaching $36, according to UBS. Estimates also lowered as new strategy could take 2-3 years to implement.

Corning ( GLW) estimates increased at Morgan Stanley through 2013, Morgan Stanley said. Expect lower prices to drive TV demand. Equal-weight rating.

GrafTech International ( GTI) numbers lowered at Jefferies. Shares of GTI now seen reaching $23, Jefferies said. Estimates also lowered on European electric market uncertainty. Buy rating.

Knight Capital ( KCG) numbers cut at Goldman. Shares of KCG now seen reaching $13, according to Goldman Sachs. Estimates also reduced, given slower core trading activity. Buy rating.

Lowe's ( LOW) target boosted at Morgan Stanley. Shares of LOW now seen reaching $23, according to Morgan Stanley. Company has improved clarity on potential margin expansion. Underweight rating.

Novellus Systems ( NVLS) target raised at UBS to $44, according to UBS. Lam's offfer to acquire company at 28% premium. Neutral rating.

Onyx Pharmaceuticals ( ONXX) added to Conviction Buy List at Goldman. Company should report lots of positive data in the coming quarters.

VeriFone Systems ( PAY) numbers raised at Citigroup. Shares of PAY now seen reaching $53, according to Citigroup. Company raised guidance to account for pending Point acquisition. Buy rating.

Charles Schwab ( SCHW) numbers cut at Goldman. SCHW estimates were reduced through 2013, Goldman Sachs said. Net interest margins and trading activity are declining. New $12 price target.

ViroPharma ( VPHM) numbers raised at Oppenheimer. Shares of VPHM now seen reaching $32, Oppenheimer said. Estimates also raised as generic overhang is removed. Outperform rating.

ViroPharma estimates, target boosted at JMP. Shares of VPHM now seen reaching $35, according to JMP Securities. Estimates also upped, given higher expected Vancocin sales. Outperform rating.

ViroPharma numbers raised at Jefferies. Shares of VPHM now seen reaching $33, Jefferies said. Estimates also raised on approval of a new label for Vancocin. Buy rating.

>To submit a news tip, email: tips@thestreet.com.

RELATED STORIES:


Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of RealMoney.com.